Effects of newly introduced antidiabetic drugs on autophagy

M. Ashrafizadeh, H. Yaribeygi, Stephen Atkin, Amirhossein Sahebkar

Research output: Contribution to journalReview article

13 Citations (Scopus)


Diabetes mellitus is a chronic metabolic disorder that has a complex molecular and cellular pathophysiology, resulting in its dynamic progression and that may show differing responses to therapy. The incidence of diabetes mellitus increases with age and requires additive therapeutic agents for its management. SGLT2i and DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1RA) are newly introduced antidiabetic drugs that work through differing mechanisms; DPP-4 inhibitors maintain the endogenous level of GLP1; GLP-1RA result in pharmacological levels of GLP1, whilst SGLT2i act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes and in contrast to other antidiabetic drugs, do not inherently cause hypoglycemia in therapeutic doses. Autophagy as a highly conserved mechanism to maintain cell survival and homeostasis by degradation of damaged or aged organelles and components, and recognised to be increasingly important in diabetes. In the present review, we discuss the modulatory effects of these newly introduced antidiabetic drugs on the autophagy process.

Original languageEnglish
Pages (from-to)2445-2449
Number of pages5
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
Issue number4
Publication statusPublished - 1 Jul 2019



  • Autophagy
  • Diabetes mellitus
  • DPP-4
  • GRP-1
  • SGLT

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this